Skip Navigation


Annals of Oncology Advance Access originally published online on November 28, 2007
Annals of Oncology 2008 19(3):443-447; doi:10.1093/annonc/mdm540
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 7 iss...
Right arrow All Versions of this Article:
19/3/443    most recent
mdm540v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Powles, T.
Right arrow Articles by Oliver, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powles, T.
Right arrow Articles by Oliver, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

urogenital tumors

The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis

T. Powles1,*, D. Robinson2, J. Shamash1, H. Moller2, N. Tranter1 and T. Oliver1

1 Department of Medical Oncology, St Bartholomew's Hospital, London
2 Department of Medical Statistics, Thames Cancer Registry, London, UK

* Correspondence to: Dr T. Powles, Department of Medical Oncology, Barts and the London NHS Trust, St Bartholomew’s Hospital, 7th Floor Glouchester House, London EC1A 7BE, UK. Tel: +44-07932048109; Fax: +44-02087468533; E-mail: thomas.powles{at}bartsandthelondon.nhs.uk

Background: The use of adjuvant carboplatin in the management of stage I seminoma of the testis has been limited by the lack of long-term data. In this study, we address this issue for the first time.

Patients and methods: Data on 199 patients treated with single-agent carboplatin for stage I seminoma of the testis were prospectively collected. Overall mortality, deaths from circulatory disease and the incidence of second cancers were compared with expected values derived from the UK general population.

Results: The median follow-up for the cohort was 9.0 years (range 0.1–20.1). There has been no excess in overall mortality [standardised mortality ratio (SMR) 0.89; 95% CI 0.36–1.83], death from circulatory diseases (SMR 1.44; 95% CI 0.39–3.69) or the incidence of second nontestis cancers (standardised incidence ratio 0.96; 95% CI 0.26–2.45) in this group of patients. These findings also applied to specific follow-up periods of >5 or 10 years. Specifically, neither haematological nor solid nontestis tumours occurred in excess. There was an increase in the long-term development of contralateral testis cancers.

Conclusions: This study addresses some of the concerns surrounding the long-term safety of single-agent carboplatin. It also helps in planning long-term follow-up for patients receiving this form of treatment.

Key words: adjuvant, carboplatin, mortality, testis cancer, second cancers, seminoma, stage 1

Received for publication September 5, 2007. Revision received October 22, 2007. Accepted for publication October 23, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Horwich
Stage I seminoma and carboplatin risks
Ann. Onc., March 1, 2008; 19(3): 407 - 408.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.